Univ. Lille, Inserm, CHU Lille, U1008 - Controlled Drug Delivery Systems and Biomaterials, F-59000 Lille, France.
Univ. Lille, Inserm, CHU Lille, U995 - Inflammation: Regulatory Mechanisms and Interactions With Nutrition and Candidosis, F-59000 Lille, France.
Int J Pharm. 2017 Nov 25;533(1):26-33. doi: 10.1016/j.ijpharm.2017.09.037. Epub 2017 Sep 18.
The aim of this work was to prepare and characterize (in vitro and in vivo) PLGA-based microparticles loaded with an enzymatic protein derived from the helminth parasite Schistosoma haematobium: glutathione S-transferase P28GST (P28GST). This protein is not only a promising candidate vaccine against schistosomiasis, it also exhibits interesting immunomodulating effects, which can be helpful for the regulation of inflammatory diseases. Helminths express a regulatory role on intestinal inflammation, and immunization by P28GST has recently been shown to be as efficient as infection to reduce inflammation in a murine colitis model. As an alternative to the combination with a classical adjuvant, long acting P28GST microparticles were prepared in order to induce colitis prevention. PLGA was used as biodegradable and biocompatible matrix former, and a W/O/W emulsion/solvent extraction technique applied to prepare different types of microparticles. The effects of key formulation and processing parameters (e.g., the polymer molecular weight, drug loading, W/O/W phase volumes and stirring rates of the primary/secondary emulsions) on the systems' performance were studied. Microparticles providing about constant P28GST release during several weeks were selected and their effects in an experimental model of colitis evaluated. Mice received P28GST-loaded or P28GST-free PLGA microparticles (s.c.) on Day 0, and optionally also on Days 14 and 28. Colitis was induced on Day 35, the animals were sacrificed on Day 37. Interestingly, the Wallace score (being a measure of the severity of the inflammation) was significantly lower in mice treated with P28GST microparticles compared to placebo after 1 or 3 injections. As immunogenicity markers, increased anti-P28GST IgG levels were detected after three P28GST PLGA microparticle injections, but not in the control groups. Thus, the proposed microparticles offer an interesting potential for the preventive treatment of experimental colitis, while the underlying mechanism of action is still to be investigated.
这项工作的目的是制备和表征(体外和体内)负载源自寄生虫旋毛虫的酶蛋白的 PLGA 基微球:谷胱甘肽 S-转移酶 P28GST(P28GST)。这种蛋白质不仅是一种有前途的抗血吸虫病候选疫苗,而且还具有有趣的免疫调节作用,这有助于调节炎症性疾病。蠕虫在肠道炎症中表达出调节作用,最近的研究表明,P28GST 免疫接种与感染一样有效,可减少小鼠结肠炎模型中的炎症。作为与经典佐剂结合的替代方法,制备了长效 P28GST 微球以诱导结肠炎预防。PLGA 用作可生物降解和生物相容的基质形成剂,并应用 W/O/W 乳液/溶剂萃取技术来制备不同类型的微球。研究了关键配方和加工参数(例如聚合物分子量、药物负载、W/O/W 相体积和初级/次级乳液的搅拌速度)对系统性能的影响。选择了能够在数周内提供稳定的 P28GST 释放的微球,并在结肠炎模型中评估了其作用。在第 0 天,用 P28GST 负载或无 P28GST 的 PLGA 微球(皮下)处理小鼠,并在第 14 天和第 28 天可选地进行处理。在第 35 天诱导结肠炎,第 37 天处死动物。有趣的是,与安慰剂相比,接受 P28GST 微球治疗的小鼠的 Wallace 评分(衡量炎症严重程度的指标)在 1 或 3 次注射后明显降低。作为免疫原性标志物,在进行三次 P28GST-PLGA 微球注射后检测到抗 P28GST IgG 水平升高,但在对照组中没有。因此,所提出的微球为预防实验性结肠炎提供了一种有趣的潜力,而作用机制仍有待研究。